Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Polen Capital - Emerging Markets Growth Portfolio Manager | “Hugel maintained its nine-year leadership in South Korea's botulinum toxin and filler markets, supported by strong cost efficiency and expanding export channels. While Q3 profits modestly undershot expectations, upcoming U.S. FDA approvals are expected to accelerate its international growth and reinforce its global competitiveness. :contentReference[oaicite:4]{index=4} BSD Analysis: Hugel's dominance in Asia's aesthetics market and regulatory pathway into the U.S. position it for global scale expansion. Its vertically integrated production model and robust brand recognition underpin high returns on capital. As approvals broaden and margins normalize, Hugel's valuation discount offers asymmetric upside.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
